News

ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer and Shionogi, has obtained approval in Canada, for its Triumeq (dolutegravir) 50mg, abacavir 600mg, and lamivudine 300mg) to treat patients with Human Immunodeficiency Virus (HIV-1) infection. ...

The World Health Organisation (WHO) has warned West Africa may face up to 10,000 new Ebola cases per week within two months, due to the increasing number of patients. With a reported death rate...

The women – all current or former employees – are seeking $250 million in damages for claims that the drug maker allowed discriminatory and disparate pay and promotion policies and had a hostile work environment – referred to as...

Cipla Medpro subsidiary Medpro Pharmaceutica has entered into an agreement with Teva Pharmaceuticals. As part of the deal, Medpro will exclusively market Teva's pharmaceutical product portfolio in South Africa. Cipla Medpro CEO Paul Miller said:...

British drug maker GlaxoSmithKline (GSK) has signed an agreement with Aspen Global (AGI) to acquire interest in its newly established subsidiary Aspen Japan. As part of the deal, GSK will acquire a 25%...

Japan-based Daiichi Sankyo has signed an agreement to acquire US-based Ambit Biosciences, for about $410m. As part of the deal, Daiichi will pay $15 per share in cash to Ambit through a tender offer,...

Austria-based Nabriva Therapeutics has received qualified infectious disease product (QIDP) and fast-track status designation from the US Food and Drug Administration for its lefamulin (BC 3781). The designation has been granted for lefamulin...